Elevated alanine aminotransferase · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Elevated total bilirubin · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (at 1 year) · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) changes all‐cause mortality (at 1 year) compared with transarterial chemoembolisation (TACE) (very low certainty).
1 finding from 1 review
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete response plus partial response Length of · participants with unresectable hepatocellular carcinoma
1 finding from 1 review
Mortality Number of deaths at maximum · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to lower all‐cause mortality (at maximum 1‐year compared with TACE alone (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete response plus partial response Length of · participants with unresectable hepatocellular carcinoma
External beam radiotherapy (EBRT) plus transarterial… may leads to higher complete response plus partial response Length of compared with TACE alone (low certainty).
1 finding from 1 review
Elevated alanine aminotransferase Length of · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated alanine aminotransferase Length of compared with TACE alone (very low certainty).
1 finding from 1 review
Elevated total bilirubin Length of · participants with unresectable hepatocellular carcinoma
It is very uncertain whether external beam radiotherapy (EBRT) plus transarterial… changes elevated total bilirubin Length of compared with TACE alone (very low certainty).
1 finding from 1 review
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes all‐cause mortality at 1 year compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus oxaliplatin changes serious adverse events compared with 5‐fluorouracil plus cisplatin plus radiotherapy (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression of the tumour · people with advanced biliary tract carcinomas
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality: at 3 years · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
1 finding from 1 review
Proportion of participants without tumour response (CR+PR) · primary hepatocellular carcinoma
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
1 finding from 1 review
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Health‐related quality of life · primary hepatocellular carcinoma
1 finding from 1 review